Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The new drug delivery system effectively targets lung cancer cells.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Tribulus terrestris may protect the liver from drug damage.

QLT0267 stops hair follicle cell growth and movement.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

High doses of cyproterone acetate are linked to an increased risk of developing meningioma.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

GI197111X is best dissolved in Capmul MCM for trials.

A girl lost her hair due to being given the wrong medication because of a pharmacy's computer error.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.

Pimozide treatment resolved cysts and partially restored cheek fat in a man with Barraquer–Simons syndrome.

Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.

A rash from semaglutide may be due to propylene glycol, not the drug itself.

Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

A new compound effectively inhibits human 5α-reductase 1.

The model and estimator can predict drug exposure in kidney transplant patients well.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.

All four treatments for early rheumatoid arthritis had similar safety profiles.

Methotrexate is effective for rheumatoid arthritis but can cause side effects.

The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Midazolam's seizure prevention is partly due to increased neurosteroid production.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.